



INVESTOR WEBINAR

# ECS Botanic Holdings Ltd

A large-scale organic cultivator and manufacturer  
of GMP medicinal cannabis products

ASX : ECS

28 MAY 2024

# ECS Botanics

## Investment Highlights

- ✓ Successful Australian Medicinal Cannabis Cultivator and Manufacturer based in NW Victoria
- ✓ Rapidly growing global market ~\$80b; ECS addressable market ~\$8-10b
- ✓ Secured contracts with leading global cannabis companies such as Curaleaf, Illios Sante' and Tilray
- ✓ Profitable with a track record of strategy execution
- ✓ Experienced leadership team

## Strategic Plan for further Value Creation

- Margin expansion through own brand, retail strategy
- Establishment of global strategic partnerships



# The ECS Advantage

## 01 Cost

ECS has a cost advantage with fit for purpose protective cropping enclosures and production controllers, relatively low energy costs and a culture of fiscal discipline

## 02 Quality

The Company has demonstrated its ability to meet global euGMP standards and produce dried flower desired by leading global cannabis companies

## 03 Sustainable

ECS deploys organic, regenerative practices using solar energy along with community engagement and a diverse workforce

## 04 Australian

Australian patients and doctors are seeking Australian sourced products

Very few commercial scale Australian cultivators

# Large and Growing Addressable Market



## A Large and Growing Market

Globally the legal cannabis market is \$60b and growing.

Rescheduling in the USA will drive more investment in medical research

Decriminalisation whilst retaining Medical channel in Germany is ideally suited for medical market

ECS' target market is Medical ANZ and Europe, estimated to be \$8-10b


## Doctors and Patients seeking Australian grown products

Growth is being driven by patients and self medication black market users seeking legal alternatives

Driving laws being challenged with potential to substantially increase THC use

Public acceptance and positive feedback bringing medicinal cannabis into mainstream including paediatric, juvenile and palliative care

### Drug types most involved in poly-substance deaths from 2017-21



Pennington Institute Australia's Annual Overdose Report 2023



# Strategic Roadmap Summary

## Delivering on a Clear Strategy to Drive Value.

2018-2020 → 2021-2023 → 2024-2026 → 2027-2029

### Developing Capability and Confidence

- ✓ Established in 2018
- ✓ ODC Licenced in 2019
- ✓ TGA Licenced in 2020
- ✓ First Cultivation 2020

### Focused, Expanding and Growing Revenue

- ✓ Acquired Murray Meds
- ✓ Exporting to NZ and UK
- ✓ Focussed Victoria operations
- ✓ Organic certification
- ✓ Added 12 Greenhouses
- ✓ Positive EBITDA
- ✓ >A\$50m in sales contracts
- ✓ Established an expert team
- ✓ >4 tonnes production

### Drive Profitability, Innovation and Expansion

- Add 9 more greenhouses and light/heating for all year growing capability
- Scale to >13 tonnes production in line with licensed capacity
- Scale exports into existing and new markets to be >30% of Revenue
- Launch and build Avani B2C brand
- Leverage IP with VESIsorb® and Genetics through Avani brand
- Vertically integrated manufacturer of Oils, Capsule, Vapes and Pastilles
- Largest Australian exporter of flower

### Leading Australian Medicinal Cannabis Company and largest exporter

- Exporting to Asia and North America
- Exports >60% of Revenues
- Avani recognised as the leading brand in multiple markets
- ARTG listing for Avani Rapid medicinal cannabis capsules
- Carbon Neutral
- Organic Investment in expansion
- Most profitable Australian Cannabis Company

# ECS strategy

## Leveraging our advantage

### Quality dried flower

- Next generation ECS genetics are getting great reviews
- Construction of new Protective Cropping Enclosures essential to meet demand driven primary by export
- New genetics from some of the world's best breeders have been sourced and are being trialled this winter
- Ilios Santé forecasting high volumes of ECS flower following regulatory changes in Germany and site visit in May




#### Mango Passion

A soothing, earthy aroma lays the foundation for a comforting and grounding experience. Notes of deep forest freshness intermingle with a subtle zest

THC 24%

TOTAL TERPENE CONTENT 2.0%



#### Key Lime Pie

This strain offers a balanced experience with the creamy, sweet notes and a citrusy, uplifting effects of Super Silver Haze.

The buds are vibrant, displaying shades of green with hints of silver, coated in a frosty layer of trichomes.

THC: 23%

TOTAL TERPENE CONTENT: 2.2%

# ECS strategy

## Retail Expansion

- ECS secured its first B2C medicinal cannabis contract under the 'RAP' brand with a minimum annual value of \$380,000
- Launched soft gel caps
- Attracted some of the most successful and experienced medical cannabis sales professionals
- B2C model based on selling the advantages of ECS products to prescribers/general practitioners
- Additional 4 headcount including new GM Commercial and GM Supply Chain & Customer Service
- Our Australian B2B channels will benefit from new genetics, quality Australian product and new product lines



Average 17 years in Pharmaceutical sales  
All have a minimum 4 years' experience in  
Medicinal Cannabis



# The ECS Advantage

## Quality Product Range

### ECS Botanic's expands product range.

- Oils
- Dried Flower
- Vapes
- Gummies
- Soft Gel Capsules
- VESIsorb®



**VESISORB®**

A NOVEL SELF-EMULSIFYING DRUG DELIVERY SYSTEM (SEDDS) BASED ON VESISORB® FORMULATION TECHNOLOGY IMPROVING ORAL BIOAVAILABILITY OF CANNABIDIOL

### GMP Licence

- GMP licence has been expanded to include packaging, release for supply and storage of new product lines

### Expansion

- Outdoor expansion delivers record crop exceeding 6 tonnes
- New propagation and genetics room completed
- Heating and lighting being added to 6 PCE's for winter grow (4 completed)
- 9 New PCE's ordered, construction begins in June

# Questions &

# Answers

Questions





# Disclaimer

**This presentation has been prepared by ECS Botanic Holdings Limited ("Company").**

**This presentation, dated 28 May 2024, should be read in conjunction with, and subject to, all information previously released to the market by Company. This presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in the Company.**

In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. The information in this presentation is general only and does not constitute personal investment advice. Investors should assess their own personal financial circumstances, conduct their own investigations and consider seeking professional advice before making any investment decision. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

This presentation is for general information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or

recommendation in relation to the purchase or sales of shares or other securities in any jurisdiction.

Certain statements in this presentation constitute forward looking statements which are based on information available to the Company as at the date of this presentation. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its related entities, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on this presentation by any person and, to the maximum extent permitted by law, all such loss and damage is expressly disclaimed.

No representation or warranty, express or implied, is made or given by or on behalf of the Company, its related entities, or their respective directors, officers, employees,

contractors or agents about the accuracy, completeness or fairness of any information or opinions contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted.

Any opinions contained in this presentation reflect the Company's position at the date of this presentation based on information then known to the Company and are subject to change.

This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The Company has not, and will not, register the offer of any shares under the *US Securities Act of 1933*. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.